IGKV4-1 and metabolic syndrome: For such subtypes of MetS-associated OAB, nonspecific pharmacotherapies (e.g., antimuscarinics, β-3 agonist, and botulinum toxin injection) might lead to unsatisfying results, although current data remain controversial [6].